|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biliary phosphatidylcholine and lysophosphatidylcholine profiles in sclerosing cholangitis显示文摘AIM:To analyze phospholipid profiles in intrahepatic bile from patients with primary sclerosing cholangitis(PSC)and secondary sclerosing cholangitis(SSC).METHODS:Intrahepatic bile specimens collected via endoscopic retrograde cholangiography from 41 patients were analyzed.Fourteen of these patients were diagnosed with PSC,10 with SSC,11 with choledocholithiasis or no identifiable biliary disease,and 6 with cholangiocellular carcinoma(CCC).Bile acid,cholesterol,protein,and bilirubin contents as well as pancreas lipase activity in bile were determined by biochemical methods.Phosphatidylcholine(PC)and lysophosphatidylcholine(LPC)species were quantified using nanoelectrospray ionization tandem mass spectrometry.RESULTS:Bile from all the examined patient groups showed a remarkably similar PC and LPC species composition,with only minor statistical differences.Total biliary PC concentrations were highest in controls(8030±1843 mol/L)and lowest in patients with CCC(1969±981 mol/L)(P=0.005,controls vs SSC and CCC,respectively,P<0.05).LPC contents in bile were overall low(4.2%±1.8%).Biliary LPC/PC ratios and ratios of biliary PC to bilirubin,PC to cholesterol,PC to protein,and PC to bile acids showed no intergroup differences.CONCLUSION:PC and LPC profiles being similar in patients with or without sclerosing cholangitis,these phospholipids are likely not of major pathogenetic importance in this disease group. | Annika Gauss Robert Ehehalt Wolf-Dieter Lehmann Gerhard Erben Karl-Heinz Weiss Yvonne Schaefer Petra Kloeters-Plachky Adolf Stiehl Wolfgang Stremmel Peter Sauer Daniel Nils Gotthardt | 2013 | World Journal of Gastroenterology2013，19，33： | 3 |
| 2 | Endoscopic Retrograde Cholangiopancreatography in Diagnosis and Treatment of Primary Sclerosing Cholangitis显示文摘 | Daniel Gotthardt Adolf Stiehl | 2010 | Clinics in Liver Disease2010，，2： | 1 |
| 3 | Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci显示文摘 | Trine Folseraas Espen Melum Philipp Rausch Brian D. Juran Eva Ellinghaus Alexey Shiryaev Jon K. Laerdahl David Ellinghaus Christoph Schramm Tobias J. Weismüller Daniel Nils Gotthardt Johannes Roksund Hov Ole Petter Clausen Rinse K. Weersma Marcel Janse Ki | 2012 | Journal of Hepatology2012，，2： | 1 |
| 4 | Intestinal transplantation: review of operative techniques显示文摘 | Arash Nickkholgh Pietro Contin Kareem Abu‐Elmagd Mohammad Golriz Daniel Gotthardt Christian Morath Peter Schemmer Arianeb Mehrabi | 2013 | Clin Transplant2013，，： | 1 |
| 5 | Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation显示文摘 | Daniel Gotthardt Karl Weiss Christian Rupp Konrad Bode Isabella Eckerle Gerda Rudolph Janine Bergemann Petra Kloeters-Plachky Fadi Chahoud Markus Büchler Peter Schemmer Wolfgang Stremmel Peter Sauer | 2013 | Endoscopy2013，，： | 1 |
| 6 | Successful combination of direct antiviral agents in livertransplanted patients with recurrent hepatitis C virus显示文摘AIM To analyze the safety and efficiency of direct-actingantiviral(DAA) regimens in liver-transplanted patients with hepatitis C virus(HCV) reinfection.METHODS Between January 2014 and December 2016, 39 patients with HCV reinfection after liver transplantation were treated at our tertiary referral center with sofosbuvir(SOF)-based regimens, including various combinations with interferon(IFN), daclatasvir(DAC), simeprivir(SIM) and/or ledipasvir(LDV). Thirteen patients were treated with SOF + IFN ± RBV. Ten patients were treated with SOF + DAC ± RBV. Fiveteen patients were treated with fixed-dose combination of SOF + LDV ± RBV. One patient was treated with SOF + SIM + RBV. Three patients with relapse were retreated with SOF + LDV + RBV. The treatment duration was 12-24 wk in all cases. The decision about the HCV treatment was made by specialists at our transplant center, according to current available or recommended medications.RESULTS The majority of patients were IFN-experienced(29/39, 74.4%) and had a history of hepatocellular carcinoma(26/39, 66.7%) before liver transplantation. Sustained virological response at 12 wk(SVR12) was achieved in 10/13(76.9%) of patients treated with SOF + IFN ± RBV. All patients with relapse were treated with fixed-dose combination of SOF + LDV + RBV. Patients treated with SOF + DAC + RBV or SOF + LDV + RBV achieved 100% SVR12. SVR rates after combination treatment with inhibitors of the HCV nonstructural protein(NS)5 A and NS5 B for 24 wk were significantly higher, as compared to all other therapy regimens(P = 0.007). Liver function was stable or even improved in the majority of patients during treatment. All antiviral therapies were safe and well-tolerated, without need of discontinuation of treatment or dose adjustment of immunosuppression. No serious adverse events or any harm to the liver graft became overt. No patient experienced acute cellular rejection during the study period. CONCLUSION Our cohort of liver-transplanted patients achieved high rates of SVR12 after a 24-wk course of treatment, especially with combination of NS5 A and NS5 B inhibitors. | Christian Rupp Theresa Hippchen Manuel Neuberger Peter Sauer Jan Pfeiffenberger Wolfgang Stremmel Daniel Nils Gotthardt Arianeb Mehrabi Karl-Heinz Weiss | 2018 | World Journal of Gastroenterology2018，24，12： | 1 |
| 7 | Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease显示文摘 | Karl Heinz Weiss Daniel Nils Gotthardt Daniela Klemm Uta Merle Daniela Ferenci–Foerster Mark Schaefer Peter Ferenci Wolfgang Stremmel | 2011 | Gastroenterology2011，，4： | 1 |
| 8 | Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease显示文摘 | Karl Heinz Weiss Florentine Thurik Daniel Nils Gotthardt Mark Sch?fer Ulrike Teufel Franziska Wiegand Uta Merle Daniela Ferenci–Foerster Andreas Maieron Rudolf Stauber Heinz Zoller Hartmut H. Schmidt Ulrike Reuner Harald Hefter Jean Marc Trocello Roderick | 2013 | Clinical Gastroenterology and Hepatology2013，，8： | 1 |
| 9 | Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis显示文摘AIM:To evaluate the outcome of anti-tumor necrosis factor alpha(anti-TNFα) therapy in outpatients with ulcerative colitis at a tertiary referral center.METHODS:All patients with a confirmed diagnosis of ulcerative colitis undergoing therapy with infliximab and/or adalimumab at the outpatient clinic for inflammatory bowel diseases at the University Hospital Heidelberg between January 2011 and February 2014 were retrospectively enrolled.Patients with a followup period of less than 6 mo from start of anti-TNFα therapy were excluded.Medical records of all eligible individuals were carefully reviewed.Steroid-free clinical remission of a duration of at least 3 mo,colectomy rate,duration of anti-TNFα therapy,need for anti-TNFα dose escalation,and the occurrence of adverse events were evaluated as the main outcome parameters.RESULTS:Seventy-two patients were included(35 treated with infliximab,17 with adalimumab,20 with both consecutively).Median follow-up was 27 mo(range:6-87 mo).Steroid-free clinical remission was achieved by 22.2% of the patients(median duration:21 mo until end of follow-up; range:3-66 mo).Patients attaining steroid-free clinical remission displayed lower hemoglobin and albumin blood levels at the start of treatment than those who did not achieve remission.The overall colectomy rate was 20.8%.Nearly 50% of the patients underwent anti-TNFα dose escalation during the follow-up period.For both the infliximab and the adalimumab treated patients,non-response to anti-TNFα therapy was the major reason for treatment discontinuation.18.2% of the infliximab-treated patients and 13.5% of the adalimumab-treated patients had to discontinue their therapy due to adverse events.CONCLUSION:Real-life remission rates of ulcerative colitis under anti-TNFα are overall low,but some patients have a clear long-term benefit. | Enayatullah Baki Philipp Zwickel Anna Zawierucha Robert Ehehalt Daniel Gotthardt Wolfgang Stremmel Annika Gauss | 2015 | World Journal of Gastroenterology2015，21，11： | 1 |
| 10 | In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival显示文摘 | Gerda Rudolph Daniel Gotthardt Petra Kloeters-Plachky Daniel Rost Hasan Kulaksiz Adolf Stiehl | 2010 | Journal of Hepatology2010，，2： | 1 |
| 11 | Separate basolateral and apical phosphatidylcholine secretion routes in intestinally differentiated tumor cells显示文摘AIM:To investigate whether the secretion of phospha-tidylcholine(PC)in intestinal mucus occurs by apical secretion or via basolateral excretion and to determine its subsequent passage across the tight junctions to the apical mucus.METHODS:We addressed this question using the po-larized intestinally differentiated tumor cell line CaCo-2 grown on filters to confluence in Transwell culture chambers.The released PC and sphingomyelin(Sph)from apical and basolateral media were analyzed by mass spectrometry.RESULTS:The secreted PC species were identical in both compartments indicating the same intracellular origin of PC.However,PC secretion into the basolateral compart-ment was more effective,and the PC:Sph ratio in the ba-solateral compartment was signif icantly higher than that in the apical compartment(8.18 ± 1.84 vs 4.31 ± 1.22,P = 0.01).Both pathways were temperature sensitive and were unaltered in the presence of cyclosporine.CONCLUSION:The data demonstrate the PC secre-tion capacity of CaCo-2 cells and indicate two sepa-rated apical and basolateral release mechanisms. | Daniel Gotthardt Annika Braun Anke Tietje Karl Heinz Weiss Robert Ehehalt Wolfgang R Stremmel | 2009 | World Journal of Gastroenterology2009，15，46： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员